Pelthos Therapeutics reported total assets of $137.36M and total liabilities of $138.86M for the quarter ended Jun 2026. This balance sheet covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current Assets | |||||||||||||||
| Cash & EquivalentsCash & Equiv. | 0.06M | 0.05M | 0.08M | 0.02M | 0.10M | 3.77M | 2.41M | 1.25M | 0.51M | 0.13M | 0.06M | 14.25M | 17.97M | 31.98M | 24.19M |
| Cash & Current Investments | 0.06M | 0.05M | 0.08M | 0.02M | 0.10M | 3.77M | 2.41M | 1.25M | 0.51M | 0.13M | 0.06M | 14.25M | 17.97M | 31.98M | 24.19M |
| Receivables - NetNet Receivables | 7.99M | 8.86M | 11.70M | 14.48M | |||||||||||
| Receivables | 7.99M | 8.86M | 11.70M | 14.48M | |||||||||||
| Raw Materials | 0.44M | 0.68M | 0.67M | ||||||||||||
| Work In Process | 16.56M | 14.04M | 11.81M | ||||||||||||
| Finished Goods | 6.58M | 8.70M | 8.99M | ||||||||||||
| Inventory | 24.10M | 23.57M | 23.42M | 21.47M | |||||||||||
| Prepaid Assets | 0.22M | 0.16M | 0.09M | 0.86M | 0.02M | 0.01M | 3.42M | 2.96M | 2.46M | 2.84M | |||||
| Current Assets | 0.06M | 0.10M | 4.03M | 2.60M | 2.14M | 1.37M | 0.91M | 0.82M | 49.76M | 53.41M | 69.80M | 63.36M | |||
| Non-Current Assets | |||||||||||||||
| Construction in Progress | 1.74M | ||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 10.17M | 9.59M | 9.31M | 8.88M | |||||||||||
| Goodwill | 30.62M | 24.68M | 24.68M | 24.68M | |||||||||||
| Intangibles | 32.52M | 39.47M | 38.44M | 37.40M | |||||||||||
| Goodwill & Intangibles | 63.15M | 64.15M | 63.12M | 62.08M | |||||||||||
| Other Non-Current Assets | 0.06M | 0.18M | 0.75M | 0.75M | 0.72M | 0.71M | 0.07M | ||||||||
| Non-Current Assets | 76.67M | 76.99M | 75.58M | 74.00M | |||||||||||
| Assets | 0.06M | 0.10M | 4.03M | 2.60M | 2.14M | 1.37M | 0.91M | 0.82M | 126.43M | 130.40M | 145.38M | 137.36M | |||
| Liabilities | |||||||||||||||
| Current Liabilities | |||||||||||||||
| Accounts Payables | 2.99M | 4.62M | 2.41M | 0.84M | 1.28M | 1.90M | 2.60M | 4.99M | 5.67M | 2.99M | 6.15M | 5.85M | |||
| Payables | 2.99M | 4.62M | 2.41M | 0.84M | 1.28M | 1.90M | 2.60M | 4.99M | 5.67M | 2.99M | 6.15M | 5.85M | |||
| Accumulated Expenses | 0.22M | 0.65M | 0.49M | 0.36M | 308.00 | 0.02M | 11.89M | 15.36M | 12.84M | 20.75M | |||||
| Other Accumulated Expenses | 5.56M | 3.84M | 3.40M | 2.99M | |||||||||||
| Short term Debt | 2.19M | ||||||||||||||
| Current Deferred Revenue | 1.02M | 0.97M | 0.98M | 0.73M | |||||||||||
| Total Current Liabilities | 3.76M | 6.54M | 2.90M | 2.79M | 3.57M | 4.08M | 5.11M | 7.32M | 24.77M | 25.99M | 25.00M | 31.96M | |||
| Non-Current Liabilities | |||||||||||||||
| Non-Current Debt | 0.10M | 0.75M | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M | 26.36M | 26.59M | ||||||
| Convertible Debt | 31.44M | 39.12M | 43.32M | ||||||||||||
| Non-Current Deffered Revenue | 1.28M | 1.03M | 1.09M | ||||||||||||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | 12.87M | ||||||||||||||
| Operating Leases | 2.97M | 2.75M | 2.65M | 2.55M | |||||||||||
| Other Non-Current Liabilities | 26.18M | 30.05M | 31.95M | 33.34M | |||||||||||
| Total Non-Current Liabilities | 4.08M | 42.01M | 61.47M | 94.16M | 105.52M | ||||||||||
| Total Liabilities | 3.76M | 6.54M | 2.90M | 2.79M | 3.57M | 4.08M | 5.11M | 7.32M | 68.18M | 91.52M | 126.11M | 138.86M | |||
| Shareholder's Equity | |||||||||||||||
| Total Debt | 0.10M | 0.75M | 0.13M | 0.13M | 2.32M | 0.13M | 0.13M | 26.36M | 26.59M | ||||||
| Common Equity | -3.71M | -4.44M | -4.90M | -5.90M | -6.45M | 1.13M | -0.18M | -1.43M | -2.71M | -4.20M | -6.50M | 58.25M | 38.88M | 19.27M | -1.50M |
| Liabilities and Shareholders Equity | 0.06M | 0.10M | 4.03M | 2.60M | 2.14M | 1.37M | 0.91M | 0.82M | 126.43M | 130.40M | 145.38M | 137.36M | |||
| Retained Earnings | -6.14M | -13.52M | -16.08M | -17.85M | -19.55M | -21.48M | -23.44M | -26.89M | -43.13M | -64.79M | -89.87M | -113.28M | |||
| Preferred Shares | 60.00 | 60.00 |
Pull Pelthos Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=PTHS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "PTHS", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=PTHS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();